<DOC>
	<DOCNO>NCT00926380</DOCNO>
	<brief_summary>The aim study determine whether denosumab ( FDA-approved osteoporosis therapy ) , combination teriparatide ( FDA-approved osteoporosis therapy ) , increase bone mineral density either one alone postmenopausal osteoporotic woman .</brief_summary>
	<brief_title>Denosumab , Teriparatide Both Treatment Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Must satisfy A B C D : ( A ) Women age &gt; 55 ( B ) Postmenopausal ( C ) Osteoporotic high risk fracture Confirmed serum alkaline phosphatase upper normal limit explanation Liver disease ( AST ALT &gt; 2 x upper normal limit ) . Renal disease ( serum creatinine &gt; 2.0 mg/dl ) . Hypercalcemia ( Ca &gt; 10.5 mg/dL ) Elevated blood PTH ( intact PTH &gt; 65 pg/ml ) Serum 25OH vitamin D &lt; 20 ng/ml HCT &lt; 32 % . History malignancy ( except basal cell carcinoma ) radiation therapy . Significant cardiopulmonary disease include unstable coronary artery disease , stage D ACC/AHA heart failure condition investigator deems may preclude subject participate safely complete protocol procedure . Major psychiatric disease opinion investigator would preclude subject provide adequate inform consent complete protocol procedure . Excessive alcohol use substance abuse opinion investigator would preclude subject provide adequate inform consent complete protocol procedure . Known congenital acquire bone disease osteoporosis ( include osteomalacia , hyperparathyroidism , Paget 's disease ) Current use use past 6 month oral bisphosphonate Current use use within past 3 month estrogen , selective estrogen receptor modulators , calcitonin . Use oral parenteral glucocorticoid 14 day within past 6 month . Any current previous use strontium parenteral bisphosphonate . Known sensitivity mammalian cellderived drug product . Known sensitivity teriparatide excipients .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>denosumab</keyword>
	<keyword>teriparatide</keyword>
	<keyword>ForteoÂ®</keyword>
	<keyword>DXA</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>pQCT</keyword>
</DOC>